Holen Sie sich die Stockscreener-App
7.815
1.58%
-0.085
Schlusskurs vom Vortag:
$7.90
Offen:
$7.85
24-Stunden-Volumen:
90,559
Relative Volume:
0.28
Marktkapitalisierung:
$167.32M
Einnahmen:
$155.00K
Nettoeinkommen (Verlust:
$-30.01M
KGV:
-4.6796
EPS:
-1.67
Netto-Cashflow:
$-11.98M
1W Leistung:
-0.83%
1M Leistung:
+3.39%
6M Leistung:
+23.41%
1J Leistung:
-33.94%
1-Tages-Spanne:
$7.70
$8.10
1-Wochen-Bereich:
$7.60
$8.67
52-Wochen-Spanne:
$4.32
$12.72
Inmune Bio Inc Stock (INMB) Company Profile
Firmenname
Inmune Bio Inc
Sektor
Branche
Telefon
(858) 964-3720
Adresse
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Vergleichen Sie INMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
7.84 | 167.32M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.00 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
630.58 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.42 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.30 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-05-24 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-21 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-22 | Bestätigt | Maxim Group | Buy |
| 2020-09-01 | Eingeleitet | BTIG Research | Buy |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com
(INMB) Technical Data - news.stocktradersdaily.com
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks
INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa
INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com
INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq
INmune Bio secures key patent opinion for CORDStrom platform - Investing.com
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan
INmune Bio Receives Favorable Patentability Opinion for CORDStro - GuruFocus
INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus
INmune Bio Partners with Cell and Gene Therapy Catapult - MSN
INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus
INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha
INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq
INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan
Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World
Trend Tracker for (INMB) - news.stocktradersdaily.com
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq
INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq
INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK
Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia
Raymond James maintains INmune Bio stock with $23 target - Investing.com India
Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey
Scotiabank Remains a Buy on Inmune Bio (INMB) - The Globe and Mail
INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus
INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa
INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan
(INMB) On The My Stocks Page - news.stocktradersdaily.com
What to Expect from INmune Bio's Earnings - Benzinga
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World
INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha
Finanzdaten der Inmune Bio Inc-Aktie (INMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inmune Bio Inc-Aktie (INMB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):